Sunday 18 October 2026
Export FHTX’s income statement to Excel — free account
Foghorn Therapeutics Inc.
FHTX Healthcare Biotechnology
Foghorn Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $30.9 million, up 36.8% from fiscal 2024. In the quarter to June 2026, revenue grew 112.7%, EPS grew 64.3% and free cash flow grew 14.9%, each against the same quarter a year earlier.
1.85
0.04
−2.12%
Follow FHTX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
9.38 | 11.78 | 11.00 | 12.57 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(19.32) | (13.16) | (15.27) | (16.34) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.36 | 5.93 | 6.47 | 5.98 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.34) | (1.92) | (2.32) | (1.66) | |
EV/FCF |
(2.34) | (1.91) | (2.32) | (1.65) | |
Quick Ratio |
3.31 | 2.87 | 2.68 | 2.13 | |
Current Ratio |
3.36 | 2.92 | 2.73 | 2.16 | |
Net Debt/EBITDA |
18.23 | 8.51 | 6.85 | 10.08 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.17 | 0.12 | 0.13 | 0.10 | |
Operating CF/Net income |
2.48 | 1.27 | 1.03 | 1.19 | |
Capex/Depreciation |
0.13 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
115.25% | 558.89% | 238.41% | 245.33% | |
Selling, General and Administrative Expense of Revenue |
39.53% | 201.44% | 73.50% | 81.59% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
15.87% | 72.94% | 24.23% | 33.52% | |
Graham Net Nets |
(0.33) | (0.33) | (0.42) | (0.36) | |
Graham Number |
5.03 | 5.36 | 6.73 | 6.01 | |
Earnings Yield |
(20.08%) | (24.27%) | (21.67%) | (23.11%) | |
Free Cash Flow Yield |
(24.46%) | (26.31%) | (25.33%) | (28.84%) | |
Revenue per Share |
0.23 | 0.05 | 0.15 | 0.13 | |
Operating CF per Share |
(0.25) | (0.36) | (0.35) | (0.30) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.25) | (0.36) | (0.35) | (0.30) | |
Cash per Share |
2.37 | 2.66 | 2.54 | 2.88 | |
Shareholders Equity per Share |
(1.15) | (1.10) | (1.72) | (1.42) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.15) | (1.10) | (1.72) | (1.42) | |
Free Cash Flow |
(17.89) | (25.27) | (22.27) | (18.86) | |
Working Capital |
119.47 | 123.66 | 103.50 | 99.03 | |
Capital Expenditures |
(0.05) | — | 0.00 | 0.00 | |
Net Current Asset Value |
(114.39) | (110.51) | (143.37) | (110.50) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
3.26 | 3.69 | 4.03 | 3.33 | |
Average Assets |
214.81 | 240.43 | 241.04 | 256.67 | |
Average Common Equity |
(78.85) | (69.03) | (77.01) | (58.97) |
Columns are period end dates